Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The S&P 500 Index rose 11.7% in Q4 and 26.3% for the year. Investors became more comfortable that the U.S. Federal Reserve was done with raising interest rates, leading to a decrease of over 70 basis points in 10-year U.S. Treasury yields. The Federal Reserve’s core Personal Consumption Expenditures (PCE) Price Index has been moderating on a year-over-year basis, easing concerns about interest rates. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.
Carillon Eagle Growth & Income Fund featured stocks like AstraZeneca PLC (NASDAQ:AZN) in its Q4 2023 investor letter. Headquartered in Cambridge, the United Kingdom, AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company. On March 8, 2024, AstraZeneca PLC (NASDAQ:AZN) stock closed at $66.50 per share. One-month return of AstraZeneca PLC (NASDAQ:AZN) was 8.29%, and its shares gained 2.03% of their value over the last 52 weeks. AstraZeneca PLC (NASDAQ:AZN) has a market capitalization of $206.177 billion.
Carillon Eagle Growth & Income Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its fourth quarter 2023 investor letter:
“AstraZeneca PLC (NASDAQ:AZN) posted lackluster performance in the fourth quarter, particularly in October surrounding the European Society for Medical Oncology meeting, where AstraZeneca presented two underwhelming clinical datasets for a new cancer drug. This was coupled with concerns around a potential new competitor for AstraZeneca’s largest drug in the lung cancer space.”
A doctor wearing a lab coat standing beside shelves of medications, representing the biopharmaceutical company’s efforts in drug candidate development.
AstraZeneca PLC (NASDAQ:AZN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. At the end of the fourth quarter, AstraZeneca PLC (NASDAQ:AZN) was held by 48 hedge fund portfolios, down from 49 in the previous quarter, according to our database.
We discussed AstraZeneca PLC (NASDAQ:AZN) in another article and shared the list of fastest growing biotech companies in the US. In addition, please check out our hedge fund investor letters Q4 2023 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- 15 Most Honest Cities in the World
- 15 Best Nachos in The US
- 15 Highest Paying Countries for Animators
Disclosure: None. This article is originally published at Insider Monkey.